Diabetes
Refine Search
Pharmaceutical
In final guidance published this morning by UK drugs watch dog the National Institute for Health and Care Excellence (NICE), USA-based ophthalmic biopharma specialist Alimera Sciences’ fluocinolone acetonide intravitreal implant Iluvien is recommended as an option for the treatment of chronic diabetic macular edema. 27 November 2013
Pharmaceutical
The US Food and Drug Administration yesterday (November 25) lifted some severe limitations on the prescribing of UK pharma giant GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone). 26 November 2013
Pharmaceutical
It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries gaining approval for important new drugs, one in Europe and the other in the USA, on Friday. 25 November 2013
Pharmaceutical
At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a series of recommendation, including positive opinions for the approval of five new drugs. 22 November 2013
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing of NovoRapid PumpCart in Europe, Danish insulin giant Novo Nordisk announced this morning. 22 November 2013
Pharmaceutical
US pharma major Eli Lilly plans to invest more than $700 million to enhance its global insulin manufacturing capacity in Puerto Rico, France and China, as well as in Indianapolis, home to Lilly's global headquarters. 14 November 2013
Pharmaceutical
Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating a small molecule compound, bardoxolone methyl licensed from privately-held USA-based Reata Pharmaceuticals, in chronic kidney disease patients with type 2 diabetes in Japan. 11 November 2013
Pharmaceutical
US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued leadership in delivering innovative medicines for patients with serious disease,” dropping new research in the areas of diabetes, hepatitis C and neuroscience. 8 November 2013
Pharmaceutical
Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common stock of fellow USA-based specialty drugmaker Santarus for $32.00 per share in cash (without interest). 8 November 2013
Pharmaceutical
US biotech firm Regeneron Pharmaceuticals says its partner German drug major Bayer has submitted an application for marketing authorization in the European Union for Eylea (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME). 7 November 2013
Pharmaceutical
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and tolerability of Trajenta (linagliptin) in people with type 2 diabetes and liver disease. 7 November 2013
Pharmaceutical
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian countries felt that the complexity of managing type 2 diabetes is “underestimated". 6 November 2013
Biotechnology
San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia. 5 November 2013
Pharmaceutical
Danish insulin giant Novo Nordisk announced on Friday that the US Food and Drug Administration has approved the prefilled insulin pens NovoRapid FlexTouch and Levemir FlexTouch. 3 November 2013
Pharmaceutical
Danish insulin giant Novo Nordisk reported sales of 61.9 billion ($11.3 billion) Danish kroner in the first nine months of 2013, up 13% the like 2012 period. Its shares were down 4.3% in morning trading after the results missed analysts’ forecasts. 31 October 2013
Pharmaceutical
Danish insulin giant Novo Nordisk said on Friday that it is recalling certain batches of its prefilled insulin product NovoMix30 FlexPen for the treatment of diabetes in Austria, Belgium, Czech Republic, Denmark, France, Germany, Iceland, Luxemburg, Netherlands, Norway and Slovakia. 27 October 2013
Pharmaceutical
An agreement worth more than $500 million between privately-held Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group and Chinese pharmaceutical conglomerate Fosun Pharma, was signed in Athens, Greece, on October 24. 25 October 2013
Pharmaceutical
The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by 2019, at a compound annual growth rate of 10.2%, forecasts business intelligence provider GBI Research. 25 October 2013
Pharmaceutical
PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. 22 October 2013
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian drugmaker Wockhardt after deficiencies identified by a recent inspection. 18 October 2013
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze